{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:17:15Z","timestamp":1790781435261,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"DOI":"10.7759\/cureus.63615","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T22:01:32Z","timestamp":1719871292000},"source":"Crossref","is-referenced-by-count":3,"title":["Pneumonitis Incidence in Patients With Metastatic Non-small Cell Lung Cancer on Immunotherapy: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Sakditad","family":"Saowapa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natchaya","family":"Polpichai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pharit","family":"Siladech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalothorn","family":"Wannaphut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasawee","family":"Tanariyakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuuwadith","family":"Wattanachayakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pakin","family":"Lalitnithi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"WHO. World Health Organization. 2023 [cited 2023 Nov 26]. Lung cancer. https.\/\/www.who.int\/news-room\/fact-sheets\/detail\/lung-cancer."},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: current treatment and future advances","volume":"5","author":"Zappa C","year":"2016","unstructured":"Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016, 5:288-300.","journal-title":"Transl Lung Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel RL","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023, 73:17-48. 10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31105","article-title":"Immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"124","author":"Assi HI","year":"2018","unstructured":"Assi HI, Kamphorst AO, Moukalled NM, Ramalingam SS. Immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer. 2018, 124:248-61. 10.1002\/cncr.31105","journal-title":"Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh K","year":"2018","unstructured":"Suresh K, Voong KR, Shankar B, et al.. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol. 2018, 13:1930-9. 10.1016\/j.jtho.2018.08.2035","journal-title":"J Thorac Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.11.021","article-title":"Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years","volume":"49","author":"Cufer T","year":"2013","unstructured":"Cufer T, Ovcaricek T, O'Brien ME. Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur J Cancer. 2013, 49:1216-25. 10.1016\/j.ejca.2012.11.021","journal-title":"Eur J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013257.pub2","article-title":"Single or combined immune checkpoint inhibitors compared to first\u2010line platinum\u2010based chemotherapy with or without bevacizumab for people with advanced non\u2010small cell lung cancer","volume":"2021","author":"Ferrara R","year":"2021","unstructured":"Ferrara R, Imbimbo M, Malouf R, et al.. Single or combined immune checkpoint inhibitors compared to first\u2010line platinum\u2010based chemotherapy with or without bevacizumab for people with advanced non\u2010small cell lung cancer. Cochrane Database Syst Rev. 2021, 2021:CD013257. 10.1002\/14651858.CD013257.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"De Velasco G","year":"2017","unstructured":"De Velasco G, Je Y, Boss\u00e9 D, et al.. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients. Cancer Immunol Res. 2017, 5:312-8. 10.1158\/2326-6066.CIR-16-0237","journal-title":"Cancer Immunol Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed\u00a0death 1 and programmed death-ligand 1 inhibitors\u00a0in\u00a0non-small cell\u00a0lung\u00a0cancer: a systematic review and meta-analysis of trials","volume":"152","author":"Khunger M","year":"2017","unstructured":"Khunger M, Rakshit S, Pasupuleti V, et al.. Incidence of pneumonitis with use of programmed\u00a0death 1 and programmed death-ligand 1 inhibitors\u00a0in\u00a0non-small cell\u00a0lung\u00a0cancer: a systematic review and meta-analysis of trials. Chest. 2017, 152:271-81. 10.1016\/j.chest.2017.04.177","journal-title":"Chest"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2219454","article-title":"The safety and efficacy of immunotherapy and palliative radiotherapy in patients with metastatic non-small cell lung cancer: a systematic review and meta-analysis of 13 prospective studies","volume":"23","author":"Zhou D","year":"2023","unstructured":"Zhou D, Zhao N, Xu H, et al.. The safety and efficacy of immunotherapy and palliative radiotherapy in patients with metastatic non-small cell lung cancer: a systematic review and meta-analysis of 13 prospective studies. Expert Rev Anticancer Ther. 2023, 23:761-73. 10.1080\/14737140.2023.2219454","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11472-3","article-title":"The timing of durvalumab administration affects the risk of pneumonitis in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"23","author":"Yang Z","year":"2023","unstructured":"Yang Z, Zhong W, Luo Y, Wu C. The timing of durvalumab administration affects the risk of pneumonitis in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis. BMC Cancer. 2023, 23:962. 10.1186\/s12885-023-11472-3","journal-title":"BMC Cancer"},{"key":"ref12","article-title":"","author":"Higgins JPT","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, et al.. Cochrane Handbook for Systematic Reviews of Interventions [Internet], 2nd Edition. . John Wiley & Sons, Chichester, UK; 2019. https:\/\/onlinelibrary.wiley.com\/doi\/book\/10.1002\/9781119536604."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins JP","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002, 21:1539-58. 10.1002\/sim.1186","journal-title":"Stat Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.11.019","article-title":"CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations","volume":"127","author":"Felip E","year":"2020","unstructured":"Felip E, Ardizzoni A, Ciuleanu T, et al.. CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. Eur J Cancer. 2020, 127:160-72. 10.1016\/j.ejca.2019.11.019","journal-title":"Eur J Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.04.039","article-title":"Updated efficacy analysis including secondary population results for Oak: a randomized phase III study of atezolizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer","volume":"13","author":"Fehrenbacher L","year":"2018","unstructured":"Fehrenbacher L, von Pawel J, Park K, et al.. Updated efficacy analysis including secondary population results for Oak: a randomized phase III study of atezolizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2018, 13:1156-70. 10.1016\/j.jtho.2018.04.039","journal-title":"J Thorac Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.01.006","article-title":"Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial","volume":"14","author":"Wu YL","year":"2019","unstructured":"Wu YL, Lu S, Cheng Y, et al.. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. J Thorac Oncol. 2019, 14:867-75. 10.1016\/j.jtho.2019.01.006","journal-title":"J Thorac Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE- 042): a randomised, open-label, controlled, phase 3 trial. The","volume":"393","author":"Mok TSK","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, et al.. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE- 042): a randomised, open-label, controlled, phase 3 trial. The. Lancet. 2019, 393:1819-30. 10.1016\/S0140-6736(18)32409-7","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei H","year":"2021","unstructured":"Borghaei H, Gettinger S, Vokes EE, et al.. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021, 39:723-33. 10.1200\/JCO.20.01605","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher L","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M, et al.. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016, 387:1837-46. 10.1016\/S0140-6736(16)00587-0","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE- 010): a randomised controlled trial","volume":"387","author":"Herbst RS","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, et al.. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE- 010): a randomised controlled trial. Lancet. 2016, 387:1540-50. 10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.9929","article-title":"Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Gettinger S","year":"2016","unstructured":"Gettinger S, Rizvi NA, Chow LQ, et al.. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016, 34:2980-7. 10.1200\/JCO.2016.66.9929","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon EB","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, et al.. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015, 372:2018-28. 10.1056\/NEJMoa1501824","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck M","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al.. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016, 375:1823-33. 10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi NA","year":"2015","unstructured":"Rizvi NA, Mazi\u00e8res J, Planchard D, et al.. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015, 16:257-65. 10.1016\/S1470-2045(15)70054-9","journal-title":"Lancet Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer J","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, et al.. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015, 373:123-35. 10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei H","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, et al.. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015, 373:1627-39. 10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger SN","year":"2015","unstructured":"Gettinger SN, Horn L, Gandhi L, et al.. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015, 33:2004-12. 10.1200\/JCO.2014.58.3708","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx008","article-title":"Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial","volume":"28","author":"Hui R","year":"2017","unstructured":"Hui R, Garon EB, Goldman JW, et al.. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol. 2017, 28:874-81. 10.1093\/annonc\/mdx008","journal-title":"Ann Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30500-9","article-title":"Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE- 001): 3-year results from an open-label, phase 1 study. The","volume":"7","author":"Leighl NB","year":"2019","unstructured":"Leighl NB, Hellmann MD, Hui R, et al.. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE- 001): 3-year results from an open-label, phase 1 study. The. Lancet Respir Med. 2019, 7:347-57. 10.1016\/S2213-2600(18)30500-9","journal-title":"Lancet Respir Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-021-02926-y","article-title":"Patterns of immunotherapy-induced pneumonitis in patients with non-small-cell lung cancer: a case series","volume":"15","author":"Picard S","year":"2021","unstructured":"Picard S, Goh D, Tan A, Sikotra N, Gabbay E, Clay T. Patterns of immunotherapy-induced pneumonitis in patients with non-small-cell lung cancer: a case series. J Med Case Rep. 2021, 15:332. 10.1186\/s13256-021-02926-y","journal-title":"J Med Case Rep"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.008","article-title":"Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials","volume":"31","author":"Magee DE","year":"2020","unstructured":"Magee DE, Hird AE, Klaassen Z, Sridhar SS, Nam RK, Wallis CJ, Kulkarni GS. Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials. Ann Oncol. 2020, 31:50-60. 10.1016\/j.annonc.2019.10.008","journal-title":"Ann Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108353","article-title":"Adverse events of immunotherapy in non-small cell lung cancer: a systematic review and network meta-analysis","volume":"102","author":"Zhou C","year":"2022","unstructured":"Zhou C, Li M, Wang Z, An D, Li B. Adverse events of immunotherapy in non-small cell lung cancer: a systematic review and network meta-analysis. Int Immunopharmacol. 2022, 102:108353. 10.1016\/j.intimp.2021.108353","journal-title":"Int Immunopharmacol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert C","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al.. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015, 372:2521-32. 10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.09.46","article-title":"PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer","volume":"10","author":"Shankar B","year":"2018","unstructured":"Shankar B, Naidoo J. PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer. J Thorac Dis. 2018, 10:S4034-7. 10.21037\/jtd.2018.09.46","journal-title":"J Thorac Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31043","article-title":"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature","volume":"124","author":"Pillai RN","year":"2018","unstructured":"Pillai RN, Behera M, Owonikoko TK, et al.. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature. Cancer. 2018, 124:271-7. 10.1002\/cncr.31043","journal-title":"Cancer"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino M","year":"2016","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016, 2:1607-16. 10.1001\/jamaoncol.2016.2453","journal-title":"JAMA Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/srep44173","article-title":"PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis","volume":"7","author":"Wu J","year":"2017","unstructured":"Wu J, Hong D, Zhang X, Lu X, Miao J. PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. Sci Rep. 2017, 7:44173. 10.1038\/srep44173","journal-title":"Sci Rep"},{"key":"ref38","article-title":"Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab","volume":"7","author":"Rickard F","year":"2018","unstructured":"Rickard F, Hyams C, Low AT. Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab. BMJ Case Rep. 2018, 7:2018224485.","journal-title":"BMJ Case Rep"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay M","year":"2017","unstructured":"Delaunay M, Cadranel J, Lusque A, et al.. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017, 50:10.1183\/13993003.00050-2017","journal-title":"Eur Respir J"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang DY","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al.. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:1721-8. 10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/220081-pneumonitis-incidence-in-patients-with-metastatic-non-small-cell-lung-cancer-on-immunotherapy-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T22:01:38Z","timestamp":1719871298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/220081-pneumonitis-incidence-in-patients-with-metastatic-non-small-cell-lung-cancer-on-immunotherapy-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.63615","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,1]]}}}